Bioxyne Limited (ASX:BXN)
Australia
· Delayed Price · Currency is AUD | Market Cap | 54.12M |
| Revenue (ttm) | 17.33M |
| Net Income (ttm) | 2.24M |
| Shares Out | 2.16B |
| EPS (ttm) | 0.00 |
| PE Ratio | 19.36 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3,965,518 |
| Average Volume | 3,486,858 |
| Open | 0.0260 |
| Previous Close | 0.0250 |
| Day's Range | 0.0240 - 0.0260 |
| 52-Week Range | 0.0040 - 0.0530 |
| Beta | 0.12 |
| RSI | 49.46 |
| Earnings Date | May 28, 2025 |
About Bioxyne
Bioxyne Limited, a life sciences and consumer health products company, engages in the manufacture and distribution of consumer health products, patented probiotics, health supplements, therapeutic goods, and alternative medicines. The company manufactures, commercializes, and distributes plant-based wellness products and supplements, including cannabinoids, cannabis extracts, cannabis pastilles, THC flowers, vapes, oral liquids, nootropic and skin care products, and mushroom complexes. It also develops various functional food products, such as ... [Read more]
Financial Performance
In 2024, Bioxyne's revenue was 9.64 million, an increase of 81.98% compared to the previous year's 5.30 million. Losses were -13.33 million, 586.9% more than in 2023.
Financial StatementsNews
Bioxyne Delivers Australia's First Pharmaceutical Cannabis Gummies, Scales Up Manufacturing Capabilities
Australian life sciences and health products company Bioxyne Limited (ASX: BXN) announced Wednesday that its fully-owned subsidiary, Breathe Life Sciences ( BLS), has successfully manufactured and de...